Lemborexant Pill
Phase 2
Lemborexant Pill is one of 14 therapeutic programs targeting Post-Operative Delirium. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
13
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
17 competitors in Post-Operative Delirium
#DrugCompanyPhaseTrials
1Exelon
NovartisApproved
Cymbalta
Alnylam PharmaceuticalsApproved
Haldol
DDePuy Orthopaedics
Approved
Precedex
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Rozerem
TakedaPhase 2
Dayvigo
EisaiPhase 2
Namenda
SStanford University
Approved
Riboflavin
CCornea and Laser Eye Institute
Phase 2
Microcrystalline Cellulose
XXenon Pharmaceuticals Inc.
Phase 2
Anerem
AAcacia Pharma Ltd
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Lemborexant Pill. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]
- Company
- BBeijing Tiantan Hospital